30 closest matches · ranked by relevance
Acute Pancreatitis (AP) · Gallstone Pancreatitis · Alcoholic Pancreatitis
Primary: Change in C-reactive Protein (C-RP) From Admission Baseline at One Week. — 86.2; 75.8; 116.4; 127.2 mg/L — p=0.5796
Acute Pancreatitis
Primary: Change in C-Reactive Protein (CRP) — 48.4; 60.6; 62; 154 mg/L — p=0.62
Acute Pancreatitis · Intra-abdominal Hypertension
Primary: Percent Change of IAP After Treatment — -18.7; -5.4; -27.2; -20.0 percent change of IAP
Pancreatitis, Chronic; Diabetes; Transplant
Primary: Maximal Acute C-peptide Response to Glucose (ACRmax) — 1.06; 1.52; 1.29 ng/mL*min
Acute Pancreatitis
Primary: Systemic Inflammatory Response Syndrome (SIRS) Score — -0.96; -1 score on a scale — p=0.87
Acute Pancreatitis
Primary: The T2* Values in the Diagnosis of AP — 25.86; 21.06 ms — p=<0.01
Acute Pancreatitis · Intestinal Bacteria Flora Disturbance · Intestinal Dysfunction
Primary: Number of Participants With Gastrointestinal Failure Score Equal 0 — 12; 14 Participants
Acute Pancreatitis
Primary: Exploratory: Percentage Change in IL-2 Production Relative to Pre-dose Values — -55.5 percentage of change in IL-2 production
Acute Pancreatitis · Systemic Inflammatory Response Syndrome
Primary: The Safety and Tolerability of CM4620-IE in Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome (SIRS) or Hypoxemia. — 7; 5; 3; 0…
Pancreas Tumor · Pancreatitis
Primary: 60-day ≥ Grade II Complication Rate — 72; 76 Participants — p=0.804
Pancreatitis · Pancreas Divisum · Pancreatitis, Acute
Primary: Reduce the Risk of Subsequent Acute Pancreatitis Episodes by 33% — 32; 26 Participants
Walled Off Pancreatic Necrosis
Primary: Number of Participants With Resolution of WON With Endoscopic Drainage — 39 Participants
Locally Advanced Pancreatic Adenocarcinoma
Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants
Chronic Pancreatitis
Primary: Islet Graft Function — 233; 354 ng/ml*min
Acute Pancreatitis · Systemic Inflammatory Response Syndrome
Primary: Median Time to Solid Food Tolerance, With gMCP Modeling Analysis for Dose-response Relationship — 67.0; 64.0; 78.0; 66.0 Hours — p=0.3184
Post-ERCP Acute Pancreatitis
Primary: Sensitivity and Specificity of Urine Trypsinogen-2 Dipstick Testing for the Diagnosis of Post-ERCP Pancreatitis — 11.1; 91; 4.4; 96.5 percentage of participants
Pancreatic Fistula
Primary: Number of Patients With Pancreatic Fistula — 9; 8 participants
Pancreatic Cancer
Primary: Overall Survival Rate at 6 Months — 58 percentage of participants
Injury of Body of Pancreas
Primary: Number of Participants With Biochemical Leak/Grade B Fistula/Grade C Fistula — 25; 16; 3; 5 Participants
Pancreatic Duct Stone · Pancreatic Duct Stricture · Pancreatic Duct Dilatation
Primary: Percent Change in Average Daily Pain Score on the Numeric Rating Scale — -36.6; -53.7 Percent Change
Abdominal Abscess · Pelvic Abscess
Primary: Percentage of Patients Requiring Surgical Debridement for a Persistent Abscess Within 30 Days Following Initial Drainage — 3; 7 participants
Pancreatic Neoplasms · Adenocarcinoma
Primary: Anti-tumor Effect as Measured by the Proportion of Patients Free of Disease-progression at Six Months After Treatment Initiation — 28; 14 percent of patients with PFS
Surgery · Infection
Primary: The Number of Patients With Infections — 11; 10 Participants
Chronic Pancreatitis · Pancreatectomy · Pancreatic Exocrine Insufficiency
Primary: Change of Coefficient of Fat Absorption (CFA) (%) Between Baseline and End of Double-blind (DB) Period. — 31.93; 8.72 Percentage — p=<0.0001
Acute Pancreatic Necrosis · Acute Pancreatitis · Necrotizing Pancreatitis
Primary: Safety: Number of Participants With Device Related Complications — 0 Participants
Pancreatic Ductal Adenocarcinoma
Primary: Objective Response Rate — 0 Participants
Pancreatic Fistulae
Primary: Decreased Secretions — 1 participants
Pancreatic Neoplasms · Digestive System Neoplasms · Neoplasms by Site
Primary: Kaplan Meier Estimate for Disease Free Survival (DFS) According to the Independent Radiological Review Committee — 19.4; 18.8 months — p=0.1824
Metastatic Pancreatic Cancer
Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001
Metastatic Pancreatic Cancer
Primary: Number of Participants With Dose-limiting Toxicities — 4; 0; 1 participants